Search Results


Your search for Martine Piccart, MD, PhD matches 22 pages

Showing 1 - 22

2018 William L. McGuire Award Nominations Now Being Accepted

Nominations are now being accepted for the William L. McGuire Award and Lectureship. The award is given annually at the San Antonio Breast Cancer Symposium in recognition of an investigator whose extraordinary and sustained achievements in translational and/or clinical research have made an impact ...

breast cancer

Study Finds Chemotherapy May Be Avoidable in Women With Early Breast Cancer at High Clinical but Low Genomic Risk on 70-Gene Signature Assay

In a phase III trial (MINDACT) reported in The New England Journal of Medicine, Cardoso et al found that adjuvant chemotherapy may be avoidable in women with early-stage breast cancer who are at high clinical risk but low genomic risk as determined by the 70-gene signature assay (MammaPrint)....

Recipients of the David A. Karnofsky Memorial Award and Lecture

David A. Karnofsky, MD, dedicated himself to the pursuit of scientific excellence and the investigation of more effective therapies for cancer for nearly 30 years, from the time he was a resident at the Collis P. Huntington Memorial Hospital for Cancer Research of Harvard University, until his...

breast cancer

Breast Cancer Research Foundation: Revitalizing Academic Research in Breast Cancer Through Drug Research Collaborative

When Evelyn H. Lauder was diagnosed with breast cancer in 1989, she became a vocal spokesperson for women’s health, and in 1993, along with Larry Norton, MD, now Deputy Physician-in-Chief for Breast Cancer Programs and Medical Director of the Evelyn H. Lauder Breast Center at Memorial Sloan...

breast cancer

First Results From MINDACT Confirm the Benefit of Genomic Profiling

The primary analysis of the MINDACT trial confirms the value of genomic profiling for patients with early breast cancer with zero to three positive lymph nodes, according to MINDACT investigators and breast cancer specialists who heard the results at the 2016 American Association of Cancer Research ...

Expert Point of View: Mark Pegram, MD & Martine Piccart, MD, PhD

Formal discussant of the ado-trastuzumab emtansine plus pertuzumab trial, Mark Pegram, MD, Director of the Breast Cancer Program at Stanford Women’s Cancer Center and Co-Director of Stanford’s Molecular Therapeutics Program, Stanford, California, said that I-SPY 2 has several strengths. They...

breast cancer

AACR 2016: MammaPrint Genetic Test Can Reduce Use of Adjuvant Chemotherapy Among Early-Stage Breast Cancer Patients

Among patients with early-stage breast cancer who were considered at high risk for disease recurrence based on clinical and biologic criteria, the MammaPrint genetic test identified a large group of patients for whom 5-year distant metastasis–free survival was equally good whether or not they ...

cost of care

Martine J. Piccart-Gebhart, MD, PhD, on Reducing the Cost and Increasing Access to Cancer Drugs

Martine J. Piccart-Gebhart, MD, PhD, of the Jules Bordet Institute, discusses the ESMO initiative to make cancer drugs affordable.

issues in oncology

Martine J. Piccart-Gebhart, MD, PhD, on New Frontiers in Imaging

Martine J. Piccart-Gebhart, MD, PhD, of the Jules Bordet Institute, and ECCO President, discusses ways in which imaging can form the solution to individualized cancer treatment.

breast cancer

Nonsignificant Improvement in Disease-Free Survival With Adjuvant Lapatinib/Trastuzumab vs Trastuzumab in Early HER2-Positive Breast Cancer

Results of a phase III trial, reported in the Journal of Clinical Oncology by Piccart-Gebhart et al, showed a modest and statistically nonsignificant increase in disease-free survival with concurrent adjuvant lapatinib (Tykerb) and trastuzumab (Herceptin) vs trastuzumab alone in patients with...

breast cancer

One Year of Trastuzumab Remains the Standard of Care in HER2-positive Breast Cancer

For HER2-positive early breast cancer, 1 year of treatment with trastuzumab (Herceptin)—rather than 6 months or 2 years—remains the standard of care, based on two pivotal studies presented at the 2012 European Society for Medical Oncology (ESMO) Congress. The optimal duration of anti-HER2 adjuvant ...

breast cancer

Research Roundup from San Antonio: New Data on Triple-negative, HER2-positive, Local, and Advanced Breast Cancer 

The 2012 San Antonio Breast Cancer Symposium featured more than 2,500 abstracts and lectures, including timely research in the field and discussions for scientists and clinicians alike. In addition to nearly two dozen in-depth reports from the meeting, The ASCO Post brings readers the following...

American Association for Cancer Research Inaugurates the First Class of Fellows of the AACR Academy

The American Association for Cancer Research (AACR) inaugurated the first class of Fellows of the AACR Academy at the association’s annual meeting held this month in Washington, DC. The AACR Academy has been created to recognize and honor distinguished scientists whose major scientific...

Leading Investigators Honored for Outstanding Contributions to the Field of Oncology

Each year through its Special Awards Program, ASCO recognizes researchers, patient advocates, and leaders of the global oncology community who, through their work, have made significant contributions to enhancing cancer care. These recipients of ASCO’s highest, most prestigious awards collectively...

issues in oncology

ESMO President Martine Piccart, MD, PhD, on the Importance of Diagnostics in Move From Stratified to Personalized Care 

We are now living in an era of stratified oncology. The European Cancer Congress (ECC) 2013 held recently in Amsterdam provided many opportunities to attendees, including chance for discussions with basic and translational scientists, researchers, pathologists, and clinicians, as well as time for...

global cancer care

A Vision of Independent Clinical Research in South America

Clinical research is vital for the development and improvement of methods designed to prevent and treat cancer. The majority of clinical trials take place in the developed world through sponsored pharmaceutical research companies.1 The corresponding lack of research in developing countries results...

Recipients of the David A. Karnofsky Memorial Award and Lecture

2014: H.M. (Bob) Pinedo, MD, PhD 2013: Martine J. Piccart, MD, PhD 2012: Kanti R. Rai, MD 2011: Kenneth Anderson, MD 2010: Daniel D. Von Hoff, MD, FACP 2009: Clara D. Bloomfield, MD 2008: V. Craig Jordan, OBE, PhD, DSc 2007: Robert A. Kyle, MD, MACP 2006: Dennis J. Slamon, MD, PhD 2005: Charles L....

breast cancer

ALTTO Trial Finds Dual Anti-HER2 Therapy No Better Than Trastuzumab Alone

The highly anticipated results from the phase III ALTTO trial show no additional benefit for adding lapatinib (Tykerb) to trastuzumab (Herceptin) in the adjuvant treatment of HER2-positive breast cancer.1 The results were presented at the 2014 ASCO Annual Meeting’s Plenary Session by Martine J....

2015 Recipients of the Susan G. Komen Brinker Awards for Scientific Distinction to Present Lectures at San Antonio Breast Cancer Symposium

Susan G. Komen has announced the recipients of the 2015 Brinker Awards for Scientific Distinction, which honors leading scientists who have made the most significant advances in breast cancer research and medicine.  The 2015 recipients of the Brinker Awards for Scientific Distinction are Myles A....

Expert Point of View: Martine Piccart, MD, PhD

Martine Piccart, MD, PhD, Professor of Oncology at the Université Libre de Bruxelles, Belgium, and President of the European Cancer Organisation, said she found it “distressing” to see such large variations in 5-year survival across European countries. “I would like to stress the fact that these...

breast cancer

ASCO 2014: Adding Lapatinib to Adjuvant Trastuzumab Does Not Improve Outcomes in Early-Stage HER2-Positive Breast Cancer

A large phase III study, ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation), found no statistically significant differences in 4-year disease-free survival among women with early HER2-positive breast cancer who received adjuvant treatment that combined the HER2-targeted drugs...

breast cancer

NeoALTTO Trial Links Pathologic Complete Response to Clinical Outcomes

Final results of the phase III NeoALTTO trial have confirmed the value of pathologic complete response to dual HER2 blockade in the neoadjuvant setting. The achievement of pathologic complete response was associated with significantly improved event-free survival and overall survival in some women...